"Epirubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Descriptor ID |
D015251
|
MeSH Number(s) |
D02.455.426.559.847.562.050.200.175.200 D04.615.562.050.200.175.200 D09.408.051.059.200.175.200
|
Concept/Terms |
Epirubicin- Epirubicin
- 4'-Epidoxorubicin
- 4' Epidoxorubicin
- 4'-Epi-Doxorubicin
- 4' Epi Doxorubicin
- 4'-Epi-Adriamycin
- 4' Epi Adriamycin
- 4'-Epiadriamycin
- 4' Epiadriamycin
- 4'-Epi-DXR
- 4' Epi DXR
Ellence- Ellence
- Pharmorubicin
- Farmorubicine
- Farmorubicin
|
Below are MeSH descriptors whose meaning is more general than "Epirubicin".
Below are MeSH descriptors whose meaning is more specific than "Epirubicin".
This graph shows the total number of publications written about "Epirubicin" by people in this website by year, and whether "Epirubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 0 | 2 | 2 |
2018 | 0 | 3 | 3 |
2019 | 0 | 1 | 1 |
2020 | 0 | 2 | 2 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epirubicin" by people in Profiles.
-
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041). Eur J Cancer. 2023 05; 184:1-9.
-
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res. 2020 10 23; 22(1):111.
-
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups. J Med Chem. 2020 09 24; 63(18):10339-10351.
-
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. Int J Cancer. 2019 08 01; 145(3):857-868.
-
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol. 2018 08 01; 36(22):2281-2287.
-
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol. 2018 05 01; 36(13):1308-1316.
-
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. Clin Breast Cancer. 2018 04; 18(2):175-183.
-
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol. 2017 Aug 01; 28(8):1803-1810.
-
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. Clin Breast Cancer. 2017 07; 17(4):279-285.
-
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial. Anticancer Res. 2016 09; 36(9):4771-6.